Lung Cancer, Nonsmall Cell Clinical Trials

55 clinical trials for Lung Cancer, Nonsmall Cell across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Prospective Data Collection Initiative on Thoracic Malignancies — RECRUITING
• ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC — RECRUITING · PHASE2
• Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy — RECRUITING · PHASE1
• Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer — RECRUITING · NA
• A Multicenter Cancer Biospecimen Collection Study — RECRUITING
• Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy — RECRUITING · PHASE2
• Study of PRO in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay) — RECRUITING · NA
• A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) — RECRUITING · PHASE3
• I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy — RECRUITING
• Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients — COMPLETED
• Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients — ACTIVE_NOT_RECRUITING · NA
• Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients — ACTIVE_NOT_RECRUITING
• Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) — TERMINATED · PHASE2
• Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Palliative Thoracic ImmunoRT — ACTIVE_NOT_RECRUITING
• Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers — TERMINATED · PHASE1
• Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer — WITHDRAWN · PHASE2
• [18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients — COMPLETED · PHASE1
• Trial of NanoPac Intratumoral Injection in Lung Cancer — COMPLETED · PHASE2
• Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC — TERMINATED · PHASE1
• Induction Chemo-Nivo in Unresectable Stage III NSCLC — TERMINATED · PHASE2
• Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT System — WITHDRAWN
• A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery — NOT_YET_RECRUITING · PHASE2
• Cios Mobile 3D Spin for Robotic Bronchoscopy — COMPLETED
• Use of the ADL-Glittre Test in the Pre and Postoperative Period of Patients With Lung Cancer — OTHER · NA
• A Radiomic Model for Risk of Local Recurrence and DFS for T3 and T4 Non-small Cell Lung Cancer — COMPLETED
• Breathe Easier II: A Dyad-based Multiple Behavior Intervention — COMPLETED · NA
• Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) — OTHER · PHASE2
• High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases — NOT_YET_RECRUITING · PHASE2
• Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating — OTHER · NA
• Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan — OTHER · NA
• Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA — TERMINATED
• Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management — OTHER · PHASE1
• Move For Surgery - A Novel Preconditioning Program — COMPLETED · PHASE3
• Plasmodium Immunotherapy for Lung Cancer — OTHER · PHASE1
• Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity — OTHER · PHASE1
• Prediction Model of ICIs Combined With Chemotherapy in Advanced NSCLC — OTHER
• This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. — TERMINATED
• Efficacy and Safety of Perioperative Use of Breztri Aerosphere to Relieve Cough After Lobectomy — OTHER · NA
• FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer — COMPLETED · NA
• Effect of Exercise Training in Lung Cancer — COMPLETED · NA
• Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer — COMPLETED · PHASE2
• Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. — COMPLETED · PHASE2
• Pulmonary Function After Arterial Sleeve Lobectomy — COMPLETED
• A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients — OTHER · PHASE1
• The Influence of Cancer Stem-cells on Risk of Relapse in Patients Harboring Adenocarcinoma and Squamous Cell Carcinoma of the Lung — COMPLETED
• Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment — OTHER
• X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases — OTHER · PHASE2
• Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection — COMPLETED · PHASE2
• Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China — COMPLETED

Refine this search